Steranco Healthcare has received approval from the U.S. Food and Drug Administration (USFDA) for Lacosamide through the Abbreviated New Drug Application (ANDA) pathway under application number 220366. This approval marks another addition to the growing portfolio of generic products entering the U.S. pharmaceutical market and highlights continued activity in the neurological therapeutics segment.
Lacosamide is an anticonvulsant medication used in the management of seizure disorders, including partial-onset seizures and certain generalized seizure conditions. Generic approvals continue to play an important role in improving patient access to cost-effective therapies while maintaining stringent standards for quality, safety, and therapeutic equivalence established by the USFDA.
REFERENCE: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220366